# A Study of TCD601 in de Novo Renal Transplant Recipients

> **NCT05669001** · PHASE2 · COMPLETED · sponsor: **ITB-Med LLC** · enrollment: 76 (actual)

## Conditions studied

- Renal Transplantation

## Interventions

- **BIOLOGICAL:** TCD601
- **BIOLOGICAL:** belatacept
- **DRUG:** ATG
- **DRUG:** TAC
- **DRUG:** MPA
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT05669001
- **Lead sponsor:** ITB-Med LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-28
- **Primary completion:** 2026-04-10
- **Final completion:** 2026-04-10
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669001, "A Study of TCD601 in de Novo Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05669001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*